RxDoctor Payments Data

Marely Santiago Vazquez, MD

Dermatology · Palmas del Mar, Humacao, PRNPI 1144776865

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,668 of the $8,253 with a category attached, or 68.7%. 15 manufacturers reported payments, led by AbbVie at 40.6% of the total. Reporting peaked in 2023 at $2,722 and has fallen 70.8% since, to $794 in 2025. Among dermatology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,253in general payments, 2019–2025

Across 193 payments — averaging $42.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Sanofi$1K
  • E.r. Squibb & Sons, L.L.C.$436
  • PBG Puerto Rico LLC$298
  • Eli Lilly Export S.A. Puerto Rico Branch$292
  • plus $982 from 9 others

What the payments were for

  • Consulting fees$1,72521%
  • Food & beverage$5,66869%
  • Education$86010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,253 in reported general payments places this provider in the 90th percentile of 108 dermatology providers in Puerto Rico.

See all dermatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,503
Medicare patients
40
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$179,988
Taltz AutoinjectorIxekizumab13$101,020
Dupixent PenDupilumab19$73,071
Betamethasone Valerate456$18,416
Ketoconazole567$11,390
Metronidazole109$6,210
Mometasone Furoate204$6,063
Calcipotriene29$5,052
Clobetasol Propionate85$5,032
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc75$4,353
Ciclopirox111$3,809
Clotrimazole226$3,643
Tacrolimus43$3,327
Triamcinolone Acetonide154$2,880
Clindamycin Phosphate56$2,416

Paid to pharmacies, not to this prescriber.

Other dermatology in Palmas del Mar, Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →